Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MY006 in Healthy Volunteers and Peanut Allergy Patients
NCT07287033Phase 1Recruiting
- Sponsor
- Mabylon AG
- Start
- Dec 2025
- Primary completion
- Apr 2027
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, triple-blind trial of MY006 in peanut allergy (6 arms), sponsored by Mabylon AG. Primary endpoint: Proportion of Subjects with Adverse Events and Serious Adverse Events at Week 26. Started Dec 2025; status: recruiting.
02
Drugs
MY006
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT07287033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07287033.